APVO — Aptevo Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671584 ·
Last close
$0.46
Market Cap
$834.5K
52W High
$25.56
52W Low
$0.45
ADV30
81,835
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,443,000 | -6,356,000 | 14,519,000 | 9,797,000 | 8,478,000 |
| Mar 2026 | 0 | — | -6,837,000 | -6,697,000 | 19,902,000 | 14,524,000 | 8,290,000 |
| Dec 2025 | 0 | — | -5,996,000 | -5,806,000 | 27,194,000 | 21,619,000 | 9,813,000 |
| Sep 2025 | 0 | — | -7,610,000 | -7,549,000 | 26,996,000 | 21,061,000 | 9,604,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,343,000
Investing CF
$0
Financing CF
$25,730,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-203.15
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-288,264,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,886,000
Pretax Income TTM
$-26,408,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,312,000 | -25,967,000 | 27,194,000 | 9,813,000 | 17,381,000 | -25,592,000 |
| Dec 2024 | 0 | -24,602,000 | -24,130,000 | 15,591,000 | 10,836,000 | 4,755,000 | -23,785,000 |
| Dec 2023 | 0 | -28,878,000 | -17,411,000 | 24,842,000 | 12,621,000 | 12,221,000 | -11,730,000 |
| Dec 2022 | 3,114,000 | -28,641,000 | 8,027,000 | 34,215,000 | 16,241,000 | 17,974,000 | -21,022,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-53,585,000
NetIncome TTM
$-28,076,000
OpCashFlow TTM
—
Assets (Latest)
$14,519,000
Forward EPS
$-10.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTIX | Protagenic Therapeutics, Inc.\new | $814.6K | $0.45 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $922.6K | $0.28 | — |
| OGEN | ORAGENICS INC | $947.5K | $0.21 | — |
| SKVI | SKINVISIBLE, INC. | $972.7K | $0.18 | — |
| GOVX | GeoVax Labs, Inc. | $1.09M | $2.01 | — |
News headlines (Yahoo Finance, 1h cache)
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
2026-11-16 13:30 · Yahoo
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
2026-11-12 21:15 · Yahoo
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
2026-11-11 14:00 · Yahoo
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
2026-11-09 13:30 · Yahoo
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
2026-11-05 13:30 · Yahoo
APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate
2026-10-27 10:33 · Yahoo
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
2026-10-26 12:05 · Yahoo
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
2026-10-14 12:46 · Yahoo
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
2026-09-24 12:05 · Yahoo
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
2026-09-03 14:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.